Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AIMMUNE THERAPEUTICS, INC.

(AIMT)
SummaryChartsNewsRatingsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Monteverde & Associates PC : Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California

10/15/2020 | 07:29pm EDT

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Northern District of California, Case No. 4:20-cv-06733-YGR, on behalf of common shareholders of Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (AIMT) who held Aimmune securities as of the close of the tender offer on October 9, 2020 (the "Class Period"), and have been harmed by Aimmune and its board of directors' (the "Board") alleged violations of Sections 14(e) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the sale of the Company to Société des Produits Nestlé S.A. ("Nestlé").

Under the terms of the sale, each share of Aimmune common stock was converted into the right to receive $34.50 in cash per share of Aimmune common stock owned. The complaint alleges that the Merger Consideration is inadequate and that the Recommendation Statement provided shareholders with materially incomplete and misleading information, in violation of Sections 14(e) and 20(a) of the Exchange Act. In particular, the complaint alleges that the Recommendation Statement contained materially incomplete and misleading information concerning: (i) financial projections for Aimmune; (ii) the valuation analyses performed by Aimmune's financial advisors J.P. Morgan Securities L.L.C. and Lazard Frères & Co. LLC, in support of their fairness opinions; and (iii) background information of the offer.

Mr. Juan Monteverde is available to personally discuss this case with you and if you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2020. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member.

Click here for more information: https://www.monteverdelaw.com/case/aimmune-therapeutics-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.  Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.  Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019).  Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave, Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com 
Tel: (212) 971-1341

Attorney Advertising. (C) 2020 Monteverde & Associates PC.  Prior results do not guarantee a similar outcome with respect to any future matter. 

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/monteverde--associates-pc-files-class-action-lawsuit-on-behalf-of-shareholders-of-aimmune-therapeutics-inc-in-the-northern-district-of-california-301153749.html

SOURCE Monteverde & Associates PC


© PRNewswire 2020
All news about AIMMUNE THERAPEUTICS, INC.
02/18PRESS RELEASE : Nestle: Nestlé reports full-year -2-
DJ
01/22AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
01/05AIMMUNE THERAPEUTICS  : European Commission approves first treatment for peanut ..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission Approves Aimmune's PALFORZIA® as Fir..
BU
2020Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
2020AIMMUNE THERAPEUTICS, INC.  : Termination of a Material Definitive Agreement, Co..
AQ
2020AIMMUNE THERAPEUTICS  : Receives Positive CHMP Opinion on PALFORZIA for the Trea..
AQ
2020MONTEVERDE & ASSOCIATES PC  : Files Class Action Lawsuit On Behalf Of Shareholde..
PR
2020AIMMUNE THERAPEUTICS  : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
More news